When added to palliative chemotherapy, trastuzumab, an anti-HER2 targeted agent, demonstrated a significant survival benefit in patients with metastatic GC.36 Therefore, HER2 is routinely tested as a strongly predictive biomarker for targeted drug therapy. The gene discussed is ERBB2; the disease is gastric cancer.